GlobeNewswire: Telix Pharmaceuticals Limited Contains the last 10 of 124 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:05:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852822/0/en/World-First-Use-of-Lightpoint-s-SENSEI-Drop-In-Gamma-Probe-in-Bladder-Cancer-Surgery-Performed-in-Spain.html?f=22&fvtc=4&fvtv=31213World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain2024-03-26T21:51:34Z<![CDATA[LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at Hospital del Mar in Barcelona, Spain.]]>https://www.globenewswire.com/news-release/2024/03/18/2848202/0/en/QDOSE-Platform-Partnership-for-Personalized-Dosimetry-in-Radiopharmaceutical-Therapy.html?f=22&fvtc=4&fvtv=31213QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy2024-03-18T21:08:36Z<![CDATA[MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO), a full-service contract research organization (CRO) based in Dresden, and its development partner, Stockholm-based Quantinm AB.]]>https://www.globenewswire.com/news-release/2024/03/11/2844204/0/en/Appointment-of-Dr-Darren-Patti-to-Group-Chief-Operating-Officer.html?f=22&fvtc=4&fvtv=31213Appointment of Dr Darren Patti to Group Chief Operating Officer2024-03-11T21:31:12Z<![CDATA[MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.]]>https://www.globenewswire.com/news-release/2024/03/04/2840035/0/en/Telix-to-Acquire-ARTMS-Inc-and-its-Advanced-Isotope-Production-Platform.html?f=22&fvtc=4&fvtv=31213Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform2024-03-04T22:42:16Z<![CDATA[MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.]]>https://www.globenewswire.com/news-release/2024/02/26/2835518/0/en/Telix-Expands-U-S-Development-and-Manufacturing-Infrastructure-with-Acquisition-of-IsoTherapeutics.html?f=22&fvtc=4&fvtv=31213Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics2024-02-26T21:27:08Z<![CDATA[MELBOURNE, Australia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.]]>https://www.globenewswire.com/news-release/2024/02/22/2833355/0/en/Telix-2023-Full-Year-Results-Inaugural-Profit-Achieved-Strong-Revenue-Growth-Underpins-Investment-in-Late-stage-Pipeline.html?f=22&fvtc=4&fvtv=31213Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline2024-02-22T08:51:00Z<![CDATA[MELBOURNE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.1]]>https://www.globenewswire.com/news-release/2024/02/07/2825600/0/en/Telix-Signs-Agreement-to-Acquire-QSAM-Biosciences-and-Its-Bone-Cancer-Targeting-Platform.html?f=22&fvtc=4&fvtv=31213Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform2024-02-07T21:43:57Z<![CDATA[MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.]]>https://www.globenewswire.com/news-release/2024/01/22/2812845/0/en/Telix-Highlights-Presentations-at-Upcoming-ASCO-Genitourinary-Cancers-Symposium-ASCO-GU-2024.html?f=22&fvtc=4&fvtv=31213Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)2024-01-22T11:00:00Z<![CDATA[MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.]]>https://www.globenewswire.com/news-release/2024/01/04/2804372/0/en/Telix-Announces-Planned-Registered-Public-Offering-and-Listing-in-the-United-States.html?f=22&fvtc=4&fvtv=31213Telix Announces Planned Registered Public Offering and Listing in the United States2024-01-04T21:59:38Z<![CDATA[MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of American Depositary Shares (“ADSs”) representing its ordinary shares in the United States (“U.S.”) and listing on the Nasdaq Global Market (“Nasdaq”). Telix’s ordinary shares will remain listed on the Australian Securities Exchange.]]>https://www.globenewswire.com/news-release/2024/01/03/2803652/0/en/Telix-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=31213Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T21:55:14Z<![CDATA[MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (US).]]>